YDR199W Antibody

What is the YYDRxG motif in antibodies and what is its significance in viral research?

The YYDRxG motif is a hexapeptide sequence found in the complementarity-determining region H3 (CDR H3) of certain antibodies. This motif is particularly significant because it facilitates antibody targeting to functionally conserved epitopes on the SARS-CoV-2 receptor binding domain (RBD). Structurally identified in antibodies such as ADI-62113 and COVA1-16, this motif forms a conserved local structure that interacts with highly conserved residues in the RBD of SARS-CoV-2 .

The significance of this motif extends beyond SARS-CoV-2, as computational searches have identified approximately 100 antibodies containing this pattern that can neutralize not only SARS-CoV-2 variants but also SARS-CoV. This suggests that the YYDRxG motif represents a common convergent solution employed by the human humoral immune system to target sarbecoviruses, including challenging variants like Omicron .

How are YYDRxG motif-containing antibodies encoded genetically?

• V(D)J recombination with specific usage of the IGHD3-22 gene

• N additions (N1 and N2) at both ends of IGHD3-22 during recombination

• Positioning that determines both CDR H3 length and the reading frame of IGHD3-22

These genetic requirements explain why YYDRxG motif-containing antibodies remain relatively rare in the human antibody repertoire. The need for a specific reading frame, site-specific somatic hypermutation, and relatively long N additions at both ends of IGHD3-22 contributes to the comparatively low frequency of these antibodies isolated from COVID-19 patients and vaccinees .

What structural features characterize the interaction between YYDRxG motif-containing antibodies and viral targets?

The interaction between YYDRxG motif-containing antibodies and their viral targets involves several key structural features :

• CDR H3 dominance: In antibodies like ADI-62113, the CDR H3 region dominates the interaction with SARS-CoV-2 RBD, contributing nearly 70% of the total buried surface area on the RBD.

• β-bulge formation: A β-bulge forms near the tip of CDR H3 after a type 1 β-turn, creating a specific structural conformation.

• Hydrophobic interactions: Residues within the motif (VH Y99, VH Y100, and VH R100b) form hydrophobic interactions with the RBD.

• Conserved binding mode: Despite differences in immunoglobulin heavy chain variable (IGHV) gene usage between different antibodies (like ADI-62113 and COVA1-16), the CDR H3 exhibits near-identical interactions with the RBD, suggesting that this motif creates a highly conserved binding mode regardless of other antibody structural variations .

How can researchers identify and characterize new antibodies containing convergent motifs similar to YYDRxG?

Identifying and characterizing new antibodies with convergent motifs similar to YYDRxG requires a multi-faceted approach:

• Computational pattern searching: Researchers can employ computational searches of antibody sequence databases for specific patterns. For example, a search for the YYDRxG pattern in over 205,000 antibody sequences identified 153 antibodies with this motif, of which 100 were isolated from COVID-19 patients and mRNA vaccinees .

• Structural analysis: X-ray crystallography should be used to confirm the binding mode and structural features of identified antibodies. This approach helped identify that the V₍H₎ 99YYDRxG100d hexapeptide forms a conserved local structure for interaction with highly conserved RBD residues .

• Immunoglobulin gene analysis: Analysis of germline gene usage can reveal enrichment patterns. For YYDRxG-containing antibodies, the IGHD3-22 gene was highly enriched (88%), indicating a specific genetic origin .

• Functional assays: Neutralization assays against multiple viral variants should be conducted to establish the breadth of protection. Similar to how researchers identified YYDRxG-containing antibodies that could neutralize SARS-CoV-2 variants and SARS-CoV .

This methodological framework can be adapted to identify other convergent antibody solutions that may exist for different viral families.

How do YYDRxG motif-containing antibodies compare with other broadly neutralizing antibodies in terms of neutralization breadth and potency?

Comparative analysis of YYDRxG motif-containing antibodies with other broadly neutralizing antibodies (bNAbs) reveals distinct patterns of neutralization breadth and potency:

• Sarbecovirus specificity: YYDRxG motif-containing antibodies demonstrate broad neutralization across SARS-CoV-2 variants and SARS-CoV, making them valuable for targeting the sarbecovirus subgenus specifically .

• Comparison with EDE antibodies: In dengue virus research, antibodies like J9 (though not specifically containing the YYDRxG motif) have shown comparable characteristics to the EDE (Envelope Dimer Epitope) class of bNAbs. J9 demonstrated complete neutralization of DENV1-4 with IC₅₀ values of 6 ng/ml, 30 ng/ml, 15 ng/ml, and 39 ng/ml, respectively, showing up to ~60 fold greater potency against some dengue serotypes compared to EDE1 C10 .

• Cross-reactivity limitations: While some bNAbs like the EDE1 subgroup can neutralize both dengue viruses and Zika virus, others like J9 showed high specificity for dengue viruses only. Similarly, YYDRxG motif-containing antibodies have specific patterns of cross-reactivity within sarbecoviruses .

• Incomplete neutralization patterns: Some antibodies (M1, B10, L8) display incomplete neutralization, with 10-50% infectivity persisting at high antibody concentrations (10 μg/ml), while others like J9 achieve complete neutralization, highlighting the importance of epitope targeting for effective neutralization .

What implications do YYDRxG motif-containing antibodies have for the development of pan-sarbecovirus vaccines?

The discovery and characterization of YYDRxG motif-containing antibodies offer several significant implications for pan-sarbecovirus vaccine development:

• Epitope-targeting strategy: The identification of the YYDRxG motif suggests an epitope-targeting strategy for vaccine design. By focusing on the functionally conserved epitope recognized by these antibodies, vaccines could potentially elicit broadly neutralizing responses against current and future sarbecoviruses .

• Immunogen design considerations: Vaccine developers should consider designs that specifically present the conserved epitope targeted by YYDRxG motif-containing antibodies in an optimal conformation to maximize the likelihood of eliciting similar antibodies.

• Genetic predisposition factors: The enrichment of IGHD3-22 gene usage in these antibodies suggests certain genetic factors may influence the development of broad neutralizing responses. Vaccine strategies might need to account for population genetic variations in IGHD3-22 distribution .

• Structural vaccine approaches: The structural knowledge of how YYDRxG motif-containing antibodies bind to conserved RBD epitopes can inform structure-based vaccine design, potentially through the creation of immunogens that specifically present these conserved epitopes in their native conformation .

Understanding the specific genetic and structural requirements for generating these antibodies can guide rational vaccine design approaches aimed at eliciting broadly protective immunity against current and future sarbecovirus threats.

What experimental approaches are most effective for isolating and characterizing YYDRxG motif-containing antibodies?

The isolation and characterization of YYDRxG motif-containing antibodies benefit from a comprehensive methodological approach:

• Single B cell isolation and sequencing:

  • Isolation of antigen-specific B cells from convalescent patients or vaccinees

  • Single-cell RNA sequencing to obtain paired heavy and light chain sequences

  • Sequence analysis to identify the YYDRxG motif within the CDR H3 region

  • Determination of germline gene usage, focusing on IGHD3-22 enrichment

• Recombinant antibody production:

  • Cloning of identified antibody sequences into expression vectors

  • Expression in appropriate cell systems (typically HEK293 cells)

  • Purification of antibodies using protein A/G affinity chromatography

  • Quality control through SDS-PAGE and mass spectrometry

• Functional characterization:

  • Binding assays: ELISA against soluble E protein and viral particles at different temperatures (e.g., ambient temperature and 37°C)

  • Dose-response neutralization assays to determine IC₅₀ values against multiple viral variants

  • Antibody-dependent enhancement (ADE) assays to assess potential enhancement concerns

• Structural characterization:

  • X-ray crystallography of antibody-antigen complexes

  • Analysis of binding interfaces using programs like PISA to calculate buried surface areas

  • Identification of key contact residues and structural motifs

• Epitope mapping:

  • Alanine-scanning mutagenesis libraries

  • Flow cytometry-based binding assays to mutant libraries

  • Generation of escape mutants through serial passage under antibody selection pressure

  • Creation of chimeric viruses with specific mutations to validate key epitope residues

These methodologies, when applied systematically, provide a comprehensive understanding of the antibodies' characteristics and potential applications.

How can researchers optimize assays to evaluate the neutralization capacity of YYDRxG motif-containing antibodies against emerging variants?

Optimizing assays to evaluate neutralization capacity against emerging variants requires careful consideration of several methodological factors:

• Pseudovirus versus live virus systems:

  • Pseudovirus systems allow for rapid evaluation of emerging variants in BSL-2 conditions

  • Live virus neutralization assays should be performed to confirm pseudovirus results

  • Correlation between the two systems should be established for each variant

• Standardization of viral input:

  • Standardize the amount of virus used in neutralization assays

  • Use infectious units rather than particle counts or genome equivalents

  • Optimize virus-to-cell ratios to ensure sensitivity in detecting neutralization differences

• Temperature and incubation conditions:

  • Test neutralization at both ambient temperature and 37°C, as incubation at higher temperatures has been shown to improve exposure of some epitopes

  • For YYDRxG motif-containing antibodies, a modest but consistent increase in binding to virus particles has been observed at 37°C compared to ambient temperature

• Readout systems:

  • Use reporter systems (luciferase, GFP) for high-throughput screening

  • Confirm key results with orthogonal methods (plaque reduction, immunofluorescence)

  • Implement automated image analysis for consistent quantification

• Controls and reference standards:

  • Include well-characterized antibodies with known neutralization profiles

  • Establish panels of reference antibodies representing different epitope classes

  • Include non-neutralizing antibodies as negative controls

• Breadth and potency metrics:

  • Calculate IC₅₀ and IC₉₀ values to assess both potency and completeness of neutralization

  • Develop composite scores that incorporate both breadth and potency

  • Consider the neutralization profile across phylogenetically diverse variants

By implementing these optimizations, researchers can generate more reliable and comparable data on the neutralization capacity of YYDRxG motif-containing antibodies against current and future variants.

What sequence-structure-function analyses can be applied to understand the contributions of specific residues within the YYDRxG motif?

Understanding the contributions of specific residues within the YYDRxG motif requires integrated sequence-structure-function analyses:

• Sequence conservation analysis:

  • Align sequences of YYDRxG motif-containing antibodies to identify conservation patterns

  • Analyze natural variants of the motif to understand permitted substitutions

  • Compare across different patient cohorts to identify convergent evolution patterns

• Structural analysis of antibody-antigen complexes:

  • Examine crystal structures to identify key interaction residues

  • Calculate buried surface areas and binding energies for each residue

  • Analyze hydrogen bonding networks, salt bridges, and hydrophobic interactions

  • For YYDRxG motif-containing antibodies, this revealed that VH Y99, VH Y100, and VH R100b form critical hydrophobic interactions with the RBD

• Systematic mutagenesis:

  • Generate point mutants of each residue within the YYDRxG motif

  • Test conservative and non-conservative substitutions

  • Assess the impact on binding affinity and neutralization potency

• Structural dynamics studies:

  • Perform molecular dynamics simulations to understand conformational flexibility

  • Analyze how mutations affect the stability of the β-bulge formation near the tip of CDR H3

  • Investigate the impact on the type 1 β-turn that precedes the motif

• Ancestral sequence reconstruction:

  • Trace the evolutionary history of YYDRxG motif-containing antibodies

  • Generate and test ancestral intermediates to understand the development of broad neutralization

  • As demonstrated with the J8/J9 lineage in dengue virus research, identify key mutations that occurred early in antibody lineages and their contribution to neutralizing activity

• Functional validation through recombinant antibody engineering:

  • Generate antibody variants with specific mutations or combinations of mutations

  • Test truncated antibody fragments to isolate CDR H3 contributions

  • Create chimeric antibodies combining different heavy and light chains to understand their independent contributions

These comprehensive analyses can provide detailed insights into the sequence-structure-function relationships of YYDRxG motif-containing antibodies, informing both fundamental understanding and applications in vaccine design and therapeutic development.